This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Phase 2 Bisantrene trial data published in European Journal of Haematology
10 November 2020 – Race Oncology Limited (ASX: RAC) is pleased to report that the clinical data from the investigator initiated Phase II clinical trial of Bisantrene in relapsed and refractory Acute Myeloid Leukaemia (R/R AML), conducted at Israel’s Sheba Medical Centre has been published.
This open label, single agent trial, led by Professor Arnon Nagler, studied patients (n=10) with relapsed or refractory Acute Myeloid Leukaemia (R/R AML) who on average had failed three prior lines of treatment. Bisantrene was found to be well tolerated, and after only a single course of treatment, an overall clinical response rate of 40% was observed (ASX Announcement: June 16 2020).
The paper, entitled “A phase II study of Bisantrene in patients with relapsed/refractory acute myeloid leukemia” by Canaani et al. concludes:
“…bisantrene induced clinical responses in 4 of 10 patients with R/R AML with acceptable toxicity. Bisantrene is somewhat similar to Thiotepa and Treosulfan in that an old drug that is being now revisited gaining a lot of interest especially due to better understanding of its intracellular mechanism of action blocking FTO, a recently discovered key factor in leukomogenesis. Further studies are needed to make evidence-based conclusions regarding the candidate role of bisantrene in AML therapeutics. While interventions targeting FLT3, IDH1, IDH2, and hedgehog signalling provide new hope, traditional cytotoxic chemotherapy retains a critical role in AML patient management. We speculate that bisantrene-based chemotherapy may have its greatest applicability to patients with extramedullary disease given the marked activity here observed with leukemia cutis, chloromas, and CNS disease. Our data reveal a particularly encouraging response in this high-risk population and support additional bisantrene clinical trials in R/R AML patients.”
The paper, which has been accepted for publication in The European Journal of Hematology and has undergone full peer review, is available via the following link: doi.org/10.1111/ejh.13544